ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Rocket Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action
New York, New York--(Newsfile Corp. - June 20, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) between February 27, 2025 and May 26, 2025, both dates inclusive (the 'Class Period'), of the important August 11, 2025 lead plaintiff deadline.
SO WHAT: If you purchased Rocket Pharmaceuticals securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
WHAT TO DO NEXT: To join the Rocket Pharmaceuticals class action, go to https://rosenlegal.com/submit-form/?case_id=40316 or call Phillip Kim, Esq. at 866-767-3653 or email [email protected] for more information. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 11, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.
DETAILS OF THE CASE: According to the lawsuit, defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of RP-A501's safety and clinical trial protocol; notably, that Rocket Pharmaceuticals knew Serious Adverse Events ('SAEs'), including death of participants enrolled in the study, were a risk. In particular, Rocket Pharmaceuticals amended the trial's protocol to introduce a novel immunomodulatory agent to the pretreatment regimen without providing this critical update to shareholders. Such statements absent these material facts caused shareholders to purchase Rocket Pharmaceuticals securities at artificially inflated prices. When the true details entered the market, the lawsuit claims that investors suffered damages.
To join the Rocket Pharmaceuticals class action, go to https://rosenlegal.com/submit-form/?case_id=40316 or call Phillip Kim, Esq. at 866-767-3653 or email [email protected] for more information.
No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.
Attorney Advertising. Prior results do not guarantee a similar outcome.
-------------------------------
Contact Information:
Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
www.rosenlegal.com
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/256319
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
26 minutes ago
- Yahoo
Is Packaging Corporation of America Underperforming the Nasdaq?
Valued at $16.8 billion by market cap, Packaging Corporation of America (PKG), based in Lake Forest, Illinois, operates as a leading U.S. producer of containerboard and corrugated packaging. Operating through its Packaging and Paper segments, PKG provides essential products like shipping containers and protective packaging to industries such as food, beverages, and industrial goods. Companies worth $10 billion or more are generally described as "large-cap stocks." PKG fits right into that category, with its market cap exceeding the threshold, reflecting its substantial size and influence in the competitive industry of packaging & containers. 2 Outstanding Stocks Under $50 to Buy and Hold Now Nvidia's Bringing Sovereign AI to Germany. Should You Buy NVDA Stock Here? A $1 Billion Reason to Buy MicroStrategy Stock Here Tired of missing midday reversals? The FREE Barchart Brief newsletter keeps you in the know. Sign up now! PKG currently trades 25.8% below its all-time high of $250.82 recorded on Nov. 25, 2024. PKG's stock has declined 5.8% over the past three months, notably underperforming the Nasdaq Composite's ($NASX) 11.7% uptick during the same time frame. In the long term, PKG stock has declined 17.3% on a YTD basis, underperforming the Nasdaq's 1.2% increase. Moreover, shares of PKG grew marginally over the past 52 weeks, also underperforming NASX's 9.4% returns over the same period. To confirm its recent downturn, PKG has been trading below its 200-day moving average since early March and below its 50-day moving average since mid-June, with some fluctuation in recent months. Despite reporting better-than-expected financials, PKG stock prices observed a marginal dip in the trading session after the release of its Q1 results on Apr. 22. The company's packaging sales experienced a solid boost during the quarter, leading to its net sales growing 8.2% year-over-year to $2.1 billion, surpassing the Street's expectations by a thin margin. Meanwhile, driven by a favorable pricing mix, its margins observed a significant expansion. This led to its adjusted EPS soaring 34.3% year-over-year to $2.31, exceeding the consensus estimates by 4.5%. Following the initial dip, PKG stock prices rose 2.2% in the subsequent trading session. Its rival, Ball Corporation (BALL), has declined 10.3% over the past year, underperforming PKG. Among the nine analysts covering the PKG stock, the consensus rating is a 'Moderate Buy.' Its mean price target of $210.22 suggests a 12.9% upside potential from current price levels. On the date of publication, Aditya Sarawgi did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Fehler beim Abrufen der Daten Melden Sie sich an, um Ihr Portfolio aufzurufen. Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten
Yahoo
26 minutes ago
- Yahoo
Medicare go-broke date pushed up three years in latest trustees report
This story was originally published on Healthcare Dive. To receive daily news and insights, subscribe to our free daily Healthcare Dive newsletter. A key trust fund underpinning Medicare's hospital benefit will go broke three years earlier than previously expected absent congressional action, threatening benefits for seniors, according to the Medicare trustees' annual report released Wednesday. The Medicare Hospital Insurance trust fund will be depleted in 2033, instead of 2036, as Medicare spending continues to outpace the program's income, the trustees — a group comprised of the HHS, Treasury and Labor secretaries, along with the Social Security commissioner — warned. The bleaker outlook is due to higher-than-expected spending for hospital care, hospice services and physician-administered drugs. The trustees called on Congress to act quickly to stabilize Medicare, though near-term action is unlikely as the Republican majority focuses on advancing their reconciliation megabill. Medicare has been teetering on the edge of insolvency for a while. But the latest report from Medicare's trustees is more dire than last year's, which projected Medicare would become insolvent in more than a decade. Now, Medicare's hospital trust fund will start running out of money in eight years — when today's 57-year-olds first become eligible for the program. The looming go-broke date is a result of the fund's substantial shortfall as Medicare costs continue to grow rapidly, trustees said in the report. Medicare costs are expected to increase from 3.8% of the gross domestic product in 2024 to 6.2% in 2050 before reaching 6.7% in 2099, the report projects. Costs to another fund that pays Parts B and D, called the Supplemental Medical Insurance trust fund, are also climbing, increasing pressure on beneficiary budgets and the federal budget. (Though, the Supplemental Medical Insurance trust fund is largely funded by premiums and general revenue that resets each year and doesn't face the same solvency concerns.) This year's estimates, which are based on current payment rates, could be conservative, trustees said. Under an alternate scenario, in which provider payments grow at a rate more consistent with underlying medical costs — a change aggressively lobbied for by physician associations — Medicare spending will rise to 8.8% of the GDP in 2099 rather than 6.7%, according to the report. The precarious footing of the federal insurance program, which covers almost 69 million people in the U.S., is due to the country's underlying demographic shifts, according to experts. More and more Americans are aging into Medicare, while at the same time the number of workers paying into its trust fund is dropping. More seniors are also selecting privatized Medicare Advantage plans, which are more expensive than traditional Medicare coverage. If and when the U.S. hits Medicare's go-broke date, the hospital trust fund, which pays hospitals and providers of post-acute services and also covers some of the cost of private Medicare Advantage plans, will have inadequate income to fund those benefits. Medicare payments would immediately be cut by 11%, according to the report. Those cuts would grow over time, likely disrupting services for seniors and reimbursement for providers. It's worth nothing that there's a significant degree of uncertainty in trustees' projections, which vary based on macroeconomic forces in a given year. For example, in 2020, in the early throes of COVID-19, the board predicted the hospital trust fund would run out by 2026. That deadline was pushed back to 2028 and then 2031 in subsequent years' reports, amid a broader economic rebound and more care shifting to cheaper outpatient settings. Still, the fund hasn't met the trustees' test for short-range financial adequacy since 2003, and has triggered funding warnings since 2018. To date, Congress has not allowed Medicare to go under. But legislators' lack of action despite years of warnings is a source of heartburn for budget hawks, Medicare advocates and physician lobbies. Experts say lawmakers need to act soon given many reforms to stabilize Medicare could take a few years to go into effect. 'The projections in this report show that change is needed to address Medicare's financial challenges,' the Medicare trustees wrote in their report. 'The sooner solutions are enacted, the more flexible and gradual they can be.' According to the Committee for a Responsible Federal Budget, restoring Medicare solvency would require Congress to boost the payroll tax rate by 14% or reduce Medicare spending by 9% — both politically unappetizing proposals. Other reforms that could curb Medicare spending, like implementing site-neutral payments or reducing overpayments in MA, have more bipartisan support but aren't a policy priority on the Hill. Republicans are currently focused on hammering out legislation to extend tax cuts from President Donald Trump's first term, cut green energy programs, fund border control and curb Medicaid spending. 'We are running out of time to phase in changes gradually and avoid harsh cuts, sharp tax increases, or unacceptable borrowing. Demagoguing this issue may be politically expedient, but it will ultimately prove ruinous for the tens of millions of Americans that rely on the programs,' Maya MacGuineas, the president of the CRFB, said in a statement Wednesday. Recommended Reading Medicare go-broke date extended to 2036, but warning bells continue ringing
Yahoo
32 minutes ago
- Yahoo
Should You Buy the Dip on Apple Stock This Year?
Apple is still driven by iPhone sales, and it failed to successfully launch the Vision Pro headset. The services segment is growing steadily, but under risk from lawsuits. Apple's stock trades at a high earnings ratio today. 10 stocks we like better than Apple › After peaking at around $260 near the end of 2024, Apple's (NASDAQ: AAPL) stock price has entered a bear market. Even with the wide stock market indices approaching new all-time highs, shares of Apple are down 25%, making it one of the worst-performing large-cap technology stocks in 2025. Investors are worried about tariffs, slowing revenue growth, and antitrust lawsuits that may impact the smartphone maker's future earnings power. Is now the right time to buy the dip on Apple stock? Let's put the numbers to the test and show why Apple is a risky big tech stock to purchase today. The iPhone is still a blockbuster consumer product. Over the last six months alone, the segment has generated more than $100 billion in revenue for Apple, making it the most popular smartphone in the world by revenue. The problem for investors is the fact sales have stagnated for the last few years. Apple has been able to consistently raise the price of new iPhones, but upgrade cycles are proving longer and longer for consumers, meaning they are going more years before buying the latest device. This is a major headwind to revenue growth. In order to expand its ecosystems of devices, Apple has made inroads into wearables like the Apple Watch and AirPods. These are successful products, but will not move the needle for Apple's $400 billion in consolidated annual revenue. To do that, Apple made its largest hardware launch since the iPhone with the Vision Pro virtual reality headset. A device that costs $3,500, the headset was supposed to be Apple's next big computing paradigm, giving its users more advanced computing tools for work and pleasure. So far, it looks like the Vision Pro has been a flop. Estimates are that unit sales are cumulatively less than 1 million, with many purchasers reportedly stopping using the device after a trial period. Apple remains a hardware provider tethered to iPhone sales, a product category that has matured. Expect more struggles to grow revenue on the hardware side of things in the years ahead unless Apple can come up with a breakthrough new computing device. The golden goose of Apple's business in the last few years has been its software and services segment. Including App Store revenue, licensing deals, and revenue from its first-party apps such as Apple Music, services revenue has grown from $13 billion in 2012 to $102 billion over the last 12 months. Services revenue comes with high profit margins, too. Services gross profit was $76 billion over the past 12 months, which is closing in on the $110 billion in gross profit the company gets from hardware products. Apple has one problem: Its services cash cow is under attack. First, the App Store monopoly on Apple devices has been broken due to a court ruling. Apple charges a 30% take rate on some transactions performed on an iPhone for application developers, and previously did not allow third-party payment methods unless users went to a mobile browser. The court ruling states that developers are allowed to now market directly to consumers to use cheaper payment methods, which could mean circumvention of Apple's payment ecosystem. Estimates vary, but App Store revenue is projected to be at least $10 billion a year in high-margin revenue for Apple. This is not the only antitrust lawsuit putting Apple's profits at risk. There is an antitrust court case that partially covers the large payment Alphabet's Google Search makes to be the default engine on Apple devices, with estimates that the payment is more than $20 billion a year in pure profit. This could greatly impact Apple's services gross profit, as well as its consolidated bottom-line earnings. Add both together, and it is clear that Apple's services division is under threat, and it's the only bright spot in the business over the last few years. Apple stock has gotten cheaper to start 2025, but that does not mean it is cheap. It currently has a price-to-earnings ratio (P/E) of about 30.5, which is higher than some of its technology peers that are growing much faster. Stocks with P/E ratios above 30 are typically reserved for companies with earnings growing at a quick pace, with strong future growth prospects. Apple's net income has not grown since 2022, making it one of the slowest-growing stocks with a high P/E ratio on the market today. That is a dangerous combination. We cannot forget to talk about tariffs. Apple is at the heart of the trade war between the United States and China, where most Apple devices are assembled. In the past, Apple has been able to negotiate its way out of high tariffs put on its devices, but this time may not go so well. High tariffs on imports to the United States would be brutal for Apple, as it is virtually stuck assembling most of its devices in China for the time being. Plus, moving to new markets or the United States comes with added expenses. There is not much to like about Apple stock today. Its key product is seeing slowing growth, the profitable services segment is under fire, and it trades at an expensive valuation. Add tariff risk, and there is no good reason to buy the dip on Apple stock today. Before you buy stock in Apple, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Apple wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $659,171!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $891,722!* Now, it's worth noting Stock Advisor's total average return is 995% — a market-crushing outperformance compared to 172% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 9, 2025 Suzanne Frey, an executive at Alphabet, is a member of The Motley Fool's board of directors. Brett Schafer has positions in Alphabet. The Motley Fool has positions in and recommends Alphabet and Apple. The Motley Fool has a disclosure policy. Should You Buy the Dip on Apple Stock This Year? was originally published by The Motley Fool Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
